Scibase AB (SCIB) - Total Liabilities

Latest as of September 2025: Skr20.50 Million SEK ≈ $2.21 Million USD

Based on the latest financial reports, Scibase AB (SCIB) has total liabilities worth Skr20.50 Million SEK (≈ $2.21 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how efficiently does Scibase AB generate cash to assess how effectively this company generates cash.

Scibase AB - Total Liabilities Trend (2012–2024)

This chart illustrates how Scibase AB's total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of Scibase AB to evaluate the company's liquid asset resilience ratio.

Scibase AB Competitors by Total Liabilities

The table below lists competitors of Scibase AB ranked by their total liabilities.

Company Country Total Liabilities
Cliq Digital AG
F:CLIQ
Germany €13.17 Million
Bakkavor Group PLC
LSE:BAKK
UK GBX884.80 Million
Southern Energy Corp
V:SOU
Canada CA$35.51 Million
Ihlas Yayin Holding A.S.
IS:IHYAY
Turkey TL2.77 Billion
RLF Agtech Ltd
AU:RLF
Australia AU$18.82 Million
Volt Resources Ltd
AU:VRC
Australia AU$7.24 Million
Trigon Metals Inc
V:TM
Canada CA$47.84 Million
Sub Sri Thai Public Company Limited
BK:SST
Thailand ฿4.62 Billion

Liability Composition Analysis (2012–2024)

This chart breaks down Scibase AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Scibase AB worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.49 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio 1.23 Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.61 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.38 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Scibase AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Scibase AB (2012–2024)

The table below shows the annual total liabilities of Scibase AB from 2012 to 2024.

Year Total Liabilities Change
2024-12-31 Skr25.08 Million
≈ $2.70 Million
+17.87%
2023-12-31 Skr21.28 Million
≈ $2.29 Million
-13.56%
2022-12-31 Skr24.62 Million
≈ $2.65 Million
+67.92%
2021-12-31 Skr14.66 Million
≈ $1.58 Million
+18.31%
2020-12-31 Skr12.39 Million
≈ $1.33 Million
-12.42%
2019-12-31 Skr14.15 Million
≈ $1.52 Million
+46.84%
2018-12-31 Skr9.63 Million
≈ $1.04 Million
-20.95%
2017-12-31 Skr12.19 Million
≈ $1.31 Million
-114.63%
2016-12-31 Skr-83.30 Million
≈ $-8.96 Million
-39.71%
2015-12-31 Skr-138.17 Million
≈ $-14.87 Million
-1641.01%
2014-12-31 Skr8.97 Million
≈ $964.88K
+19.58%
2013-12-31 Skr7.50 Million
≈ $806.90K
-84.23%
2012-12-31 Skr47.56 Million
≈ $5.12 Million
--

About Scibase AB

ST:SCIB Sweden Medical Devices
Market Cap
$18.23 Million
Skr169.40 Million SEK
Market Cap Rank
#25316 Global
#519 in Sweden
Share Price
Skr0.41
Change (1 day)
+0.00%
52-Week Range
Skr0.21 - Skr0.43
All Time High
Skr33.21
About

SciBase Holding AB (publ), a medical technology company, develops and commercializes point-of-care platforms for skin health management in Europe, the United States, North America, Asia, Oceania, and internationally. It operates through Skin Cancer and Skin Barrier Assessment segments. The company offers Nevisense and Nevisense Go point-of-care platforms to detect melanoma and non-melanoma skin c… Read more